Stock · Euronext Dublin
Should you buy Uniphar stock?
An Irish healthcare services and pharma distribution group with a dominant home market and strong recent growth. Thin distribution margins are the main trade-off. Here is our rating and how to buy it.
Key points
- Euronext Dublin: UPR. ISEQ-listed healthcare group, held in an ordinary brokerage account.
- Revenue €2.77bn in FY2024 (+8.5%); net profit up 43.3%.
- Dominant at home: 54% of the Irish wholesale pharma market.
- Distribution model means thin margins; a small dividend (0.53% yield).
01Our review
Uniphar at a glance
Uniphar is an Irish healthcare services group spanning pharma and medtech distribution, supply-chain services and product access, working with 9 of the world's top 10 pharma companies and holding about 54% of the Irish wholesale pharma market. FY2024 revenue reached €2.77bn (+8.5%), gross profit €427.6m (+9.6%) and net profit €64.2m (+43.3%), with 8.2% group organic growth and 17.6% organic growth in the Pharma division. Management targets €200m EBITDA by 2028. The trade-off is structural: distribution carries thin net margins (net profit is a low single-digit percentage of revenue), and the yield is small (0.53%), with a €35m buyback supplementing returns. A growth-and-scale story more than an income one.
Strengths
- Market leadership: about 54% of the Irish wholesale pharma market, working with 9 of the top 10 pharma firms.
- Strong FY2024 growth: revenue €2.77bn (+8.5%) and net profit up 43.3%.
- Healthy organic growth: 8.2% group, 17.6% in Pharma.
- Reasonable valuation: P/E of 15.47 as of 30 May 2025.
Watch-outs
- Thin distribution margins: net profit is a low single-digit share of a €2.77bn revenue base.
- Small income and hot momentum: 0.53% yield, and a 14-day RSI of 75.14 signalled overbought conditions at the snapshot.
02Snapshot
Uniphar in brief
Fundamentals verified as of 22 July 2026.
04Our verdict
Our verdict, backed by sources
Market leader, thin margins
A dominant Irish healthcare distributor with strong FY2024 growth and a reasonable valuation, but the distribution model runs on thin net margins and the stock had run hard into overbought territory at the snapshot. A quality domestic compounder better bought on weakness than strength.
This is analysis, not advice. The bull case: Uniphar leads its home market (about 54% share), grew FY2024 revenue 8.5% to €2.77bn and net profit 43.3%, delivered healthy organic growth (8.2% group, 17.6% in Pharma), and targets €200m EBITDA by 2028. Scale and top-tier pharma relationships support the case.
The bear case: distribution is a thin-margin business, so net profit is a low single-digit share of revenue and small operational slips matter. The shares had risen 68% over six months into an overbought RSI (75.14), so the entry price does real work here.
Our take: a high-quality domestic leader with genuine growth, but margins are structurally thin and momentum was stretched at the snapshot. Prefer weakness to strength on entry. As always, no invented price target.
05Get started
How to buy Uniphar stock
Two routes, both from regulated brokers. A broker comparison is further down.
Cash / spot
Buy the real share (cash)
You own the share and benefit from long-term appreciation. Cost is a small commission per order; no FX conversion since it trades in EUR. Best for buy-and-hold investors. Check how your account and Irish tax treatment apply.
CFD (leveraged)
Trade via CFD (leverage)
A CFD tracks the price with leverage that amplifies gains and losses; costs are the spread plus overnight financing. Short-term, risk-aware traders only; most retail CFD accounts lose money.
For long-term investors, buying the real share in an ordinary brokerage account is simplest. Compare brokers on Euronext Dublin commissions below.
06Playbook
6 practical tips for buying Uniphar
-
Mind the thin margins
Distribution earns a small net margin; watch profit trends, not just revenue growth.
-
Don't chase strength
The stock ran up 68% in six months into overbought RSI; entry price matters.
-
Track organic growth
Group organic growth (8.2%) and the Pharma division (17.6%) show the underlying momentum.
-
Watch the 2028 target
Management targets €200m EBITDA by 2028; judge progress against it.
-
Don't expect income
The 0.53% yield is small; returns depend on growth and the buyback, not dividends.
-
Diversify
A single-country healthcare leader is still a concentrated bet; size it within a portfolio.
08Where to invest
Where to buy Uniphar stock
For Uniphar, prioritise low Euronext Dublin commissions. Compare regulated brokers side by side.
Compare brokers for stocksUniphar stock FAQ
- Yes, but it is small: a 0.53% yield as of 30 May 2025, with a total 2024 dividend of €0.0192 per share (+5%), alongside a €35m share buyback. The case is growth, not income.
- Capital gains and dividend income are taxable in Ireland, and the effective treatment depends on your situation and account type. Check with your broker or a tax adviser.
- We don't publish one. We refuse to invent a figure or a fake consensus. When a credible, sourced analyst consensus exists we may cite it with its date; otherwise we say we don't have one.
Why trust HelloBrokers on this
Independent editorial team. We are not paid by Uniphar, and we don't publish invented price targets or a fake bank consensus. Ratings follow our methodology; broker referrals (disclosed on each page) fund our work and never change our verdict.
This content is for information only and is not investment advice, a recommendation or a solicitation. Past performance does not predict future returns. Investing carries a risk of capital loss; CFDs amplify that risk. Do your own research and consider professional advice before investing.